Prosetta Biosciences

Executive Summary

Prosetta Biosciences is a San Francisco-based biotechnology company focused on developing innovative small molecules that modulate the assembly of multi-protein complexes within cells. Founded in 2002, the company operates at the pre-clinical stage, leveraging its proprietary platform to identify novel therapeutics for diseases where protein complex assembly plays a critical role. The company's approach targets the dynamic interactions between proteins, offering potential advantages over traditional small molecule inhibitors by affecting complex stability and function. Despite a relatively long history, Prosetta remains private and has not disclosed its total funding or valuation. The company's pipeline is not publicly detailed, but its focus on protein complex modulation positions it in a niche area of drug discovery with potential applications in oncology, neurology, and infectious diseases. With no recent major catalysts announced, Prosetta's near-term value hinges on advancing its lead candidates toward IND-enabling studies and securing partnerships.

Upcoming Catalysts (preview)

• Q3 2026Announcement of lead candidate nomination for IND-enabling studies60% success
• TBDPresentation of preclinical data at a major scientific conference50% success
• TBDEstablishment of a strategic partnership or licensing deal30% success